Glutamine synthetase deficiency enhances CD8 T cell survival and stress resilience in the tumor microenvironment
The Journal of Immunology · 2026
DOI: 10.1093/jimmun/vkaf250 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, 2026. Verfasst von Emilie L Fisher-Gupta und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, United States. Hauptthemen laut MEDLINE: Tumor Microenvironment, CD8-Positive T-Lymphocytes, Glutamate-Ammonia Ligase. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIAID NIH HHS, The Vanderbilt Genome Editing Resource,Vanderbilt Translational Pathology Shared Resource, Department of Defense Congressionally Directed Medical Research Program.
Abstract (Originalsprache)
Cellular immunotherapy has revolutionized the treatment of hematologic malignancies yet has had limited success in the solid tumor microenvironment (TME). While insufficient nutrients can lead to T cell metabolic stress in the TME, the glutamine antagonist DON can paradoxically enhance antitumor immunity. Because DON inhibits both essential and nonessential enzymes whose impairment may contribute to dose-limiting toxicities, mechanisms underlying DON-induced antitumor activity have remained unclear. Here, we aimed to identify specific DON targets that increase T cell antitumor activity and test if more selective inhibition of glutamine metabolism could replicate the effects of DON with reduced toxicity. CRISPR screening in the TME of DON-relevant glutamine metabolizing enzymes identified some targets that were essential in tumor-infiltrating CD8 T cells, but that tumor-infiltrating CD8 T cells lacking the DON target glutamine synthetase (GS) were enriched. Upon adoptive T cell transfers, GS-deficient CD8+ T cells displayed improved survival, a higher proportion TCF-1+ Tox− stem-like cells, and greater antitumor and memory function. GS converts glutamate to glutamine and GS-deficient cells exhibited increased intracellular glutamate and reduced glutathione levels, which correlated with enhanced mitochondrial respiration and resistance to reactive oxygen species. Pharmacological inhibition of GS reduced tumor burden in multiple orthotopic murine tumor models in a manner dependent on adaptive immunity. Our findings establish GS as a key metabolic regulator of CD8+ T cells stress resilience in the TME. By preserving intracellular glutamate, GS inhibition reprograms T cells for improved survival and function, offering a promising therapeutic strategy to enhance immune-based cancer treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, TN, United States.
- Medical Scientist Training Program, Vanderbilt University, Nashville, TN, United States.
- Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, United States.
- Department of Chemical and Biomolecular Engineering, Vanderbilt University, Nashville, TN, United States.
- Center for Structural Biology, Vanderbilt University, Nashville, TN, United States.
- Department of Chemical and Physical Biology, Vanderbilt University, Nashville, TN, United States.
ORCID-Profile: Jeffrey C Rathmell
Förderung
- NIAID NIH HHS
- The Vanderbilt Genome Editing Resource,Vanderbilt Translational Pathology Shared Resource
- Department of Defense Congressionally Directed Medical Research Program
- The FCSR
- Waddell Walker Hancock Cancer Discovery Scholar Award
- NIGMS NIH HHS
- Mark Foundation for Cancer Research Endeavor
- NCI NIH HHS
Zitieren
APA
Fisher-Gupta, E. L., Hathaway, E. S., Perera, J. M., Jennings, E. Q., Chi, C., Sewell, A. E., Stone, S. H., Muka, J. E., Sinard, R. C., DeCorte, J. A., Chen, H., Wilson, J. T., Meiler, J., & Rathmell, J. C. (2026). Glutamine synthetase deficiency enhances CD8 T cell survival and stress resilience in the tumor microenvironment. The Journal of Immunology. https://doi.org/10.1093/jimmun/vkaf250
Vancouver
Fisher-Gupta EL, Hathaway ES, Perera JM, Jennings EQ, Chi C, Sewell AE, et al. Glutamine synthetase deficiency enhances CD8 T cell survival and stress resilience in the tumor microenvironment. The Journal of Immunology. 2026. doi:10.1093/jimmun/vkaf250
BibTeX
@article{FisherGupta2026,
author = {Fisher-Gupta, Emilie L and Hathaway, Emma S and Perera, Jeffrey M and Jennings, Erin Q and Chi, Channing and Sewell, Allison E and Stone, Spenser H and Muka, Jason E and Sinard, Rachael C and DeCorte, Joseph A and Chen, Heidi and Wilson, John T and Meiler, Jens and Rathmell, Jeffrey C},
title = {Glutamine synthetase deficiency enhances CD8 T cell survival and stress resilience in the tumor microenvironment},
journal = {The Journal of Immunology},
year = {2026},
doi = {10.1093/jimmun/vkaf250}
}
EUVIMED